MAPT and Alzheimer disease: A mercaptoacetamide-based class II HDACi and a hydroxamide-based class I and II HDACi both decrease β-amyloids in vitro by reducing gene expression of components and increasing degradation enzyme gene expression, which ultimately rescued learning and memory defects in AD mice while decreasing tau (Sung et al., 2013).